Cardiac Sarcoidosis Linked to Autoimmune Attack on Heart's Own Proteins
New molecular analysis reveals cardiac sarcoidosis triggers self-targeting antibodies against a desmosome protein, explaining its overlap with arrhythmic heart disease.
Summary
Researchers from Harvard, Duke, and international centers used advanced single-cell and spatial genomic techniques to map what goes wrong inside hearts affected by cardiac sarcoidosis — a mysterious disease causing dangerous arrhythmias and heart failure. They discovered that the heart's own immune cells produce self-targeting antibodies against periplakin, a protein critical to heart cell structure. This autoimmune process appears to drive ongoing inflammation, granuloma formation, and scarring. The finding explains why cardiac sarcoidosis shares symptoms with certain inherited arrhythmic heart diseases and opens potential new treatment avenues targeting B-cell activation and granuloma formation to reduce arrhythmia risk and slow disease progression.
Detailed Summary
Cardiac sarcoidosis is one of cardiology's most puzzling conditions — an inflammatory disease producing patchy granulomas and scarring throughout the heart, causing life-threatening arrhythmias, sudden cardiac death, and heart failure. Despite its severity, its underlying mechanisms have remained largely unexplained. This landmark study from Harvard's Brigham and Women's Hospital and collaborating institutions now offers the most detailed molecular portrait of the disease to date.
Researchers applied single-cell and spatial transcriptomic analyses to examine cardiac tissue from patients with cardiac sarcoidosis, profiling preserved, granulomatous, and fibrotic regions separately. This allowed them to map how different heart cell types behave in distinct disease zones, revealing dramatically different gene expression patterns across tissue types.
Key discoveries included cardiomyocytes upregulating genes linked to arrhythmias and pyroptosis (an inflammatory cell death pathway), while also secreting chemoattractant cytokines that continuously recruit immune cells. Granulomas were rich in macrophages driving cell-cell fusion and Th17 T cells promoting antibody production. In fibrotic regions, the team identified tertiary lymphoid structures harboring clonally expanded B cells — an unexpected finding in heart tissue.
Critically, antibodies reconstructed from these clonal B cells were found to target periplakin, a desmosome structural protein, rather than any microbial or allergen trigger. This identifies cardiac sarcoidosis as, at least partly, an autoimmune disease — with the heart attacking itself. The periplakin target also explains why cardiac sarcoidosis and arrhythmic desmosomal cardiomyopathies share clinical features.
These findings suggest that therapies targeting B-cell activation or granuloma formation could reduce arrhythmia burden and slow progression. The study is limited by its abstract-only availability for review, and clinical translation of autoantigen-targeted therapies will require further validation in larger cohorts.
Key Findings
- Cardiac sarcoidosis hearts harbor clonally expanded B cells producing autoantibodies targeting periplakin, a desmosome protein.
- Cardiomyocytes upregulate arrhythmogenic and pyroptosis-linked genes, potentially explaining dangerous rhythm disturbances.
- Granulomas contain macrophages driving cell fusion and Th17 T cells promoting B-cell antibody production.
- Fibrotic regions contain tertiary lymphoid structures sustaining chronic, localized autoimmune activity.
- Findings suggest B-cell activation and granuloma formation are actionable therapeutic targets to reduce arrhythmia risk.
Methodology
The study used single-cell RNA sequencing and spatial transcriptomics on human cardiac sarcoidosis tissue, profiling preserved, granulomatous, and fibrotic regions. Antibodies were reconstructed from clonally expanded cardiac B cells and screened against libraries of human peptidome, microbial, and allergen peptides to identify reactive autoantigens. This is a multi-institutional study involving centers in the US, Germany, Canada, and South Korea.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, so methodological details, sample sizes, and full results cannot be fully evaluated. The study reflects findings from a selected patient cohort and autoantigen findings require prospective validation in larger, diverse populations. Therapeutic implications, while compelling, remain speculative pending clinical trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.